- Active, not recruiting
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide & Dex RRMM
Updated: Feb 10
IFM2021_03
NCT04998786: Phase 2: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03)
Sponsor
Nantes University Hospital
This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse .
The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria.
Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.
ClinicalTrials.gov Identifier: NCT04998786
Official Title: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
First Posted : August 10, 2021
Click here to see details on ClinicalTrials.gov
2021-001587-13 ( EudraCT Number )
Drug: Ixazomib
Drug: Iberdomide
Drug: Dexamethasone Oral
Location
Europe
France